These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 24066893)
1. Novel strategies for development of next-generation glycoconjugate vaccines. Avci FY Curr Top Med Chem; 2013; 13(20):2535-40. PubMed ID: 24066893 [TBL] [Abstract][Full Text] [Related]
9. Role of O-Acetylation in the Immunogenicity of Bacterial Polysaccharide Vaccines. Berti F; De Ricco R; Rappuoli R Molecules; 2018 Jun; 23(6):. PubMed ID: 29865239 [TBL] [Abstract][Full Text] [Related]
11. Glycoconjugate vaccines. Pace D Expert Opin Biol Ther; 2013 Jan; 13(1):11-33. PubMed ID: 22992106 [TBL] [Abstract][Full Text] [Related]
12. Glycoconjugate vaccines: an update. Vella M; Pace D Expert Opin Biol Ther; 2015 Apr; 15(4):529-46. PubMed ID: 25496172 [TBL] [Abstract][Full Text] [Related]
13. An Overview of Structural Features of Antibacterial Glycoconjugate Vaccines That Influence Their Immunogenicity. Khatun F; Stephenson RJ; Toth I Chemistry; 2017 Mar; 23(18):4233-4254. PubMed ID: 28097690 [TBL] [Abstract][Full Text] [Related]
14. A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design. Avci FY; Li X; Tsuji M; Kasper DL Nat Med; 2011 Nov; 17(12):1602-9. PubMed ID: 22101769 [TBL] [Abstract][Full Text] [Related]
15. Generalized Modules for Membrane Antigens as Carrier for Polysaccharides: Impact of Sugar Length, Density, and Attachment Site on the Immune Response Elicited in Animal Models. Micoli F; Alfini R; Di Benedetto R; Necchi F; Schiavo F; Mancini F; Carducci M; Oldrini D; Pitirollo O; Gasperini G; Balocchi C; Bechi N; Brunelli B; Piccioli D; Adamo R Front Immunol; 2021; 12():719315. PubMed ID: 34594333 [TBL] [Abstract][Full Text] [Related]
16. Carrier priming effect of CRM197 is related to an enhanced B and T cell activation in meningococcal serogroup A conjugate vaccination. Immunological comparison between CRM197 and diphtheria toxoid. Pecetta S; Tontini M; Faenzi E; Cioncada R; Proietti D; Seubert A; Nuti S; Berti F; Romano MR Vaccine; 2016 Apr; 34(20):2334-41. PubMed ID: 27015733 [TBL] [Abstract][Full Text] [Related]
17. Exploring the Effect of Conjugation Site and Chemistry on the Immunogenicity of an anti-Group B Streptococcus Glycoconjugate Vaccine Based on GBS67 Pilus Protein and Type V Polysaccharide. Nilo A; Passalacqua I; Fabbrini M; Allan M; Usera A; Carboni F; Brogioni B; Pezzicoli A; Cobb J; Romano MR; Margarit I; Hu QY; Berti F; Adamo R Bioconjug Chem; 2015 Aug; 26(8):1839-49. PubMed ID: 26230938 [TBL] [Abstract][Full Text] [Related]
18. A Streptococcus pneumoniae Type 2 Oligosaccharide Glycoconjugate Elicits Opsonic Antibodies and Is Protective in an Animal Model of Invasive Pneumococcal Disease. Emmadi M; Khan N; Lykke L; Reppe K; G Parameswarappa S; Lisboa MP; Wienhold SM; Witzenrath M; Pereira CL; Seeberger PH J Am Chem Soc; 2017 Oct; 139(41):14783-14791. PubMed ID: 28945368 [TBL] [Abstract][Full Text] [Related]
19. Protection against Streptococcus suis Serotype 2 Infection Using a Capsular Polysaccharide Glycoconjugate Vaccine. Goyette-Desjardins G; Calzas C; Shiao TC; Neubauer A; Kempker J; Roy R; Gottschalk M; Segura M Infect Immun; 2016 Jul; 84(7):2059-2075. PubMed ID: 27113360 [TBL] [Abstract][Full Text] [Related]
20. Investigating the candidacy of a capsular polysaccharide-based glycoconjugate as a vaccine to combat Haemophilus influenzae type a disease: A solution for an unmet public health need. Cox AD; Williams D; Cairns C; St Michael F; Fleming P; Vinogradov E; Arbour M; Masson L; Zou W Vaccine; 2017 Oct; 35(45):6129-6136. PubMed ID: 28951087 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]